Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.71 |
| ▸ | SQLE | Q14534 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11651824 | 1.00 | KMT2A (0.71) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL4971321 | 0.90 | — | — | |
| SCHEMBL4971324 | 0.90 | — | — | |
| SCHEMBL18061197 | 0.90 | — | — | |
| SCHEMBL29770496 | 0.86 | KMT2A (0.65) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9129911 | 0.86 | KMT2A (0.71) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL18056789 | 0.86 | KMT2A (0.71) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9474782 | 0.86 | KMT2A (0.71) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11550081 | 0.86 | KMT2A (0.71) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL16125851 | 0.86 | KMT2A (0.71) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492158-B2 | (S,Z)-3,7-dimethylnon-6-en-1-ol and its use as fragrance | GIVAUDAN SA (CH) | 2025-12-09 | — | — | US | disclosed |
| US-20230167042-A1 | (S,Z)-3,7-DIMETHYLNON-6-EN-1-OL AND ITS USE AS FRAGRANCE | GIVAUDAN SA (CH) | 2023-06-01 | — | — | US | disclosed |
| EP-4126802-A1 | (S,Z)-3,7-DIMETHYLNON-6-EN-1-OL AND ITS USE AS FRAGRANCE | Givaudan SA (CH) | 2023-02-08 | — | — | EP | disclosed |
| CN-115397798-A | Improvements in or relating to organic compounds | 奇华顿股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167042-A1 | (S,Z)-3,7-DIMETHYLNON-6-EN-1-OL AND ITS USE AS FRAGRANCE | CYP51A1, DEGS1, ALG3 | KMT2A 2448/4885MAPT 3714/4885MEN1 1893/4885 |
| US-12492158-B2 | (S,Z)-3,7-dimethylnon-6-en-1-ol and its use as fragrance | CYP51A1, DEGS1, ALG3 | KMT2A 2448/4885MAPT 3714/4885MEN1 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.